SHOZO OKANO

Dr. SHOZO OKANO

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 April 2018 in Veterinary Sciences
Verified
Journal Article
Open access
PDF file
KMKenichi Maeda
Kenichi Maeda
MIMunehiro Iwasaki
Munehiro Iwasaki
YIYuki Itou
Yuki Itou
SISatomi Iwai
Satomi Iwai
SOSHOZO OKANO
SHOZO OKANO
Hyperglycemia causes perioperative complications and many anesthetics impair glucose metabolism and cause hyperglycemia. We evaluated the effects of propofol on blood glucose metabolism and insulin secretion during an intravenous glucose tolerance test (IVGTT) in dogs. Blood glucose, insulin, triglyceride, cholesterol, and free fatty acid (FFA) levels were measured in dogs during IVGTT in a conscious state and under the effect of 2.0% isoflurane, low-concentration propofol (0.2 mg/kg/min), and high-concentration propofol (0.4 mg/kg/min) anesthesia. Plasma glucose levels significantly increased in all of the treatment groups when compared with those in the conscious group. The prolonged half-life period of plasma glucose suggested that isoflurane and propofol attenuated glucose metabolism in dogs. Plasma insulin levels were significantly lower in the isoflurane group when compared with those in the other groups, whereas blood FFA levels were increased in the propofol groups when compared with the other groups. These results suggest that propofol itself does not directly raise plasma glucose levels, but attenuates glucose metabolism by accumulating FFA.

1 November 2021
Verified
Closed access
KFKensuke Furuta
Kensuke Furuta
KNKotaro Nishi
Kotaro Nishi
CPChun-Ho Park
Chun-Ho Park
KMKenichi Maeda
Kenichi Maeda
SISatomi Iwai
Satomi Iwai
SOSHOZO OKANO
SHOZO OKANO

15 February 2023 in Veterinary Sciences
Verified
Journal Article
Open access
PDF file
KSKameshima Satoshi
Kameshima Satoshi
YNYuki Nakamura
Yuki Nakamura
KUKenji Uehara
Kenji Uehara
TKTomoko Kodama
Tomoko Kodama
HYHideyuki Yamawaki
Hideyuki Yamawaki
NINaoyuki Itoh
Naoyuki Itoh
Soluble guanylate cyclase (sGC) stimulator riociguat is a relatively novel therapeutic agent for pulmonary hypertension (PH) in human medicine. Riociguat induces endothelium-independent pulmonary artery (PA) relaxation by directly activating the sGC-cyclic guanosine-3′,5′-monophosphate (cGMP) pathway in muscle cells. Although riociguat may be effective in the treatment of dogs with refractory PH, basic studies on its clinical application in veterinary medicine are lacking. The present study aimed to explore the effects of riociguat on the contractility of an isolated canine PA and the hemodynamics of dogs with acute PH. In an isolated endothelium-denuded canine PA, the effects of riociguat on endothelin (ET)-1-induced contraction and cGMP levels were investigated using the Magnus method and ELISA, respectively. The effect of riociguat on the hemodynamics of the thromboxane A2 analog U46619-induced PH model dog was examined by invasive catheterization. Riociguat increased cGMP levels and reduced ET-1-induced contraction of the isolated PA. Riociguat inhibited the U46619-induced elevation of PA pressure and pulmonary vascular resistance and increased cardiac output, but it had no effect on basal systemic blood pressure. These results demonstrate for the first time that riociguat can inhibit the elevation of PA pressure through PA relaxation via an endothelium-independent increase in cGMP in dogs with PH.

1 January 2024 in Journal of Advanced Veterinary and Animal Research
Verified
Journal Article
Open access
KMKenichi Maeda
Kenichi Maeda
DHDaiki Hotta
Daiki Hotta
TMTakuma Matsui
Takuma Matsui
SISatomi Iwai
Satomi Iwai
SOSHOZO OKANO
SHOZO OKANO
Objective: To evaluate the effect of water temperature on intramuscular injected alfaxalone anesthesia in carp (Cyprinus carpio). Materials and Methods: Six healthy adult carp (C. carpio) were intramuscularly injected with alfaxalone (2.5, 5.0, or 7.5 mg/kg) at normal water temperature (25°C) and at low water temperature (2.5 mg/kg, 15°C). The respiratory rate, heart rate (HR), and anesthesia depth (AD) were evaluated every 5 min for 30 min after administration and every 1 h after 60 min after injection. Results: The respiratory and HRs did not change significantly upon alfaxalone injection, regardless of dose. However, a dose-dependent increase in AD scores was observed. Furthermore, 2.5 mg/kg alfaxalone injected in 15°C water showed an almost equal anesthetic effect to that of 5.0 mg/kg alfaxalone in 25°C water. Conclusion: Alfaxalone is readily available, and its anesthetic effect in carp was enhanced by lowering water temperature, illustrating the possibility of intramuscular injection of alfaxalone in fish.

20 March 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
KNKotaro Nishi
Kotaro Nishi
THTakafumi Haji
Takafumi Haji
TMTakuya Matsumoto
Takuya Matsumoto
CHChisato Hayakawa
Chisato Hayakawa
KMKenichi Maeda
Kenichi Maeda
SISatomi Iwai
Satomi Iwai
Chronic kidney disease leads to high morbidity rates among humans. It is a serious disease that requires curative treatments other than kidney transplantation. Recently, we successfully established the iPS-derived generated kidney, which might produce urine. The urine can be directed to the native bladder with a stepwise peristaltic ureter system, followed by anastomosis with the recipient ureter for reconstruction of the urinary tract. However, the growth of the regenerated kidney varies significantly, whereas the time window of the anastomosis is quite narrow. Therefore, this study was conducted to evaluate the growth of transplanted metanephros with bladder periodically and noninvasively using computed tomography and ultrasonography. Ultrasonographic findings showed high correlations with computed tomographic findings and clearly evaluated metanephros with bladder. We found that the degree of growth of the metanephros with bladder after the transplantation differed in each individual. However, most of them reached the appropriate period for urinary tract reconstruction within 3 weeks after transplantation. Optimizing the stepwise peristaltic ureter system anastomosis by ultrasonography reduced long-term tubular dilation of the metanephros, thereby decreasing fibrosis caused by transforming growth factor-β. This may be significantly related to long-term maturation of fetal grafts. These results provide new insights into transplanting regenerated kidneys in higher animals. We are one step closer to the first human trial of kidney generation.

17 March 2024 in Journal of Applied Veterinary Sciences
Verified
Journal Article
Closed access
MAMasao Arisato
Masao Arisato
SOSHOZO OKANO
SHOZO OKANO
To elucidate the relationship between obesity, awakening time, and anesthesia in dogs, we conducted a comparative analysis of the awakening time following isoflurane and sevoflurane anesthesia in both standard-weight and obese groups. Six female beagle dogs within the standard weight range underwent 1-hour inhalation anesthesia with either isoflurane or sevoflurane. We recorded the time of extubation, head lift, and standing. Additionally, a parallel experiment was conducted on the same test animals after inducing obesity through nutritional management, with criteria for obesity defined as a body conditioning score of 4 or higher and a body fat percentage of 30% or higher. Under isoflurane anesthesia, we observed a tendency for a longer awakening time in the obese group compared to the standard weight group. However, this trend was not evident with sevoflurane anesthesia. Furthermore, when comparing awakening time with both anesthetics, no significant difference was found between the standard weight groups. In contrast, within the obese group, awakening time was significantly prolonged with isoflurane anesthesia compared to sevoflurane anesthesia. These results confirm that obesity contributes to delay awakening in dogs. Additionally, in the anesthesia management of obese dogs, the use of sevoflurane is anticipated to reduce awakening time compared to isoflurane.